✦ LIBER ✦

Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501)

✍ Scribed by Morrison, Vicki A.; Jung, Sin-Ho; Johnson, Jeffrey; LaCasce, Ann; Blum, Kristie A.; Bartlett, Nancy L.; Pitcher, Brandelyn N.; Cheson, Bruce D.

Book ID: 126791995
Publisher: Informa plc
Year: 2014
Tongue: English
Weight: 620 KB
Volume: 56
Category: Article
ISSN: 1042-8194
DOI: 10.3109/10428194.2014.938333

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase 2 trial of rituximab plus hyper-CV

Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma

✍ Michael Wang; Luis Fayad; Fernando Cabanillas; Fredrick Hagemeister; Peter McLau 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 119 KB

## Abstract ## BACKGROUND. Relapsed or refractory mantle cell lymphoma has a very poor prognosis. The authors evaluated the response rates and survival times of patients treated with an intense regimen known to be effective against untreated aggressive mantle cell lymphoma: rituximab plus hyper‐CV

Phase I/II trial assessing bendamustine

Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma

✍ Berenson, James R.; Yellin, Ori; Bessudo, Alberto; Boccia, Ralph V.; Noga, Steph 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 304 KB

Lenalidomide in combination with vorinos

Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial

✍ Hopfinger, Georg; Nösslinger, Thomas; Lang, Alois; Linkesch, Werner; Melchardt, 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 113 KB

Patients with chemotherapy-refractory ma

Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre phase 2 clinical trial

✍ Owen A. O’Connor; Craig Moskowitz; Carol Portlock; Paul Hamlin; David Straus; Ot 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB

Phase II Study of Vincristine Sulfate Li

Phase II Study of Vincristine Sulfate Liposome Injection (Marqibo) and Rituximab for Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma in Need of Palliative Therapy

✍ Kaplan, Lawrence D.; Deitcher, Steven R.; Silverman, Jeffrey A.; Morgan, Gareth 📂 Article 📅 2014 🏛 Elsevier 🌐 English ⚖ 203 KB

Tandem high-dose therapy in relapsed and

Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with131I-anti-CD20 antibody and stem cell rescue

✍ Karin Hohloch; Carsten Oliver Sahlmann; Vijai J. Lakhani; Gerald Wulf; Bertram G 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 233 KB